• Total revenue of $17.6 million in Q4 2025, down 4% YoY
• Gross profit margin of 81.2% in Q4 2025
• Net use of cash improved to $5.1 million in Q4 2025
• Full year 2025 revenue increased 11% to $71.6 million
• Secured $60 million credit facility with Perceptive Advisors

AVITA Medical reported financial results for the fourth quarter and full year ended December 31, 2025. Total revenue in Q4 2025 was $17.6 million, down 4% from the prior year period, due to lingering reimbursement headwinds. Gross profit margin was 81.2%, reflecting product mix and inventory-related adjustments. The company demonstrated continued financial discipline, with net cash use improving for the third consecutive quarter to $5.1 million. Operating expenses decreased 5% year-over-year. For the full year 2025, total revenue increased 11% to $71.6 million, within the company's revised guidance. Gross profit margin was 82.1%. The company reported a net loss of $48.6 million for the full year, an improvement from the prior year. In January 2026, AVITA announced the refinancing of its existing debt under a new $60 million credit facility with Perceptive Advisors, which will support the company's long-term growth. AVITA is focused on disciplined cash management, sharpening execution, and accelerating commercial momentum across its core U.S. burn and trauma center opportunity in 2026.

Full year 2026 revenue expected in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.

AVITA is focused on disciplined cash management, sharpening execution, and accelerating commercial momentum across its core U.S. burn and trauma center opportunity in 2026.